» Articles » PMID: 9188630

The Range and Distribution of Murine Central Nervous System Cells Infected with the Gamma(1)34.5- Mutant of Herpes Simplex Virus 1

Overview
Journal J Virol
Date 1997 Jul 1
PMID 9188630
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Wild-type herpes simplex virus 1 (HSV-1) multiplies, spreads, and rapidly destroys cells of the murine central nervous system (CNS). In contrast, mutants lacking both copies of the gamma(1)34.5- gene have been shown to be virtually lacking in virulence even after direct inoculation of high-titered virus into the CNS of susceptible mice (J. Chou, E. R. Kern, R. J. Whitley, and B. Roizman, Science 250:1262-1266, 1990). To investigate the host range and distribution of infected cells in the CNS of mice, 4- to 5-week-old mice were inoculated stereotaxically into the caudate/putamen with 3 x 10(5) PFU of the gamma(1)34.5- virus R3616. Four-micrometer-thick sections of mouse brains removed on day 3, 5, or 7 after infection were reacted with a polyclonal antibody directed primarily to structural proteins of the virus and with antibodies specific for neurons, astrocytes, or oligodendrocytes. This report shows the following: (i) most of the tissue damage caused by R3616 was at the site of injection, (ii) the virus spread by retrograde transport from the site of infection to neuronal cell nuclei at distant sites and to ependymal cells by cerebrospinal fluid, (iii) the virus infected neurons, astrocytes, oligodendrocytes, and ependymal cells and hence did not discriminate among CNS cells, (iv) viral replication in some neurons could be deduced from the observation of infected astrocytes and oligodendrocytes at distant sites, and (v) infected cells were being efficiently cleared from the nervous system by day 7 after infection. We conclude that the gamma(1)34.5- attenuation phenotype is reflected in a gross reduction in the ability of the virus to replicate and spread from cell to cell and is not due to a restricted host range. The block in viral replication appears to be a late event in viral replication.

Citing Articles

Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.

Kang K, Bernstock J, Totsch S, Gary S, Rocco A, Nan L Clin Cancer Res. 2022; 28(24):5419-5430.

PMID: 36239623 PMC: 9771977. DOI: 10.1158/1078-0432.CCR-22-1382.


Questioning the Extreme Neurovirulence of Monkey B Virus .

Eberle R, Jones-Engel L Adv Virol. 2018; 2018:5248420.

PMID: 29666644 PMC: 5831965. DOI: 10.1155/2018/5248420.


Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates.

Cassady K, Bauer D, Roth J, Chambers M, Shoeb T, Coleman J Mol Ther Oncolytics. 2017; 5:1-10.

PMID: 28345027 PMC: 5363760. DOI: 10.1016/j.omto.2017.02.001.


The γ134.5 Neurovirulence Gene of Herpes Simplex Virus 1 Modifies the Exosome Secretion Profile in Epithelial Cells.

Heikkila O, Ryodi E, Hukkanen V J Virol. 2016; 90(23):10981-10984.

PMID: 27630235 PMC: 5110198. DOI: 10.1128/JVI.01157-16.


Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making?.

Dey M, Auffinger B, Lesniak M, Ahmed A Future Virol. 2014; 8(7):675-693.

PMID: 24910708 PMC: 4043995. DOI: 10.2217/fvl.13.47.


References
1.
Ejercito P, Kieff E, Roizman B . Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol. 1968; 2(3):357-64. DOI: 10.1099/0022-1317-2-3-357. View

2.
Ackermann M, Braun D, Pereira L, Roizman B . Characterization of herpes simplex virus 1 alpha proteins 0, 4, and 27 with monoclonal antibodies. J Virol. 1984; 52(1):108-18. PMC: 254496. DOI: 10.1128/JVI.52.1.108-118.1984. View

3.
Jones E, Leavitt R . Retrograde axonal transport and the demonstration of non-specific projections to the cerebral cortex and striatum from thalamic intralaminar nuclei in the rat, cat and monkey. J Comp Neurol. 1974; 154(4):349-77. DOI: 10.1002/cne.901540402. View

4.
Knotts F, Cook M, Stevens J . Pathogenesis of herpetic encephalitis in mice after ophthalmic inoculation. J Infect Dis. 1974; 130(1):16-27. DOI: 10.1093/infdis/130.1.16. View

5.
Meignier B, Longnecker R, Roizman B . In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis. 1988; 158(3):602-14. DOI: 10.1093/infdis/158.3.602. View